Integrating EPA in CV risk reduction strategies: practical experience and guidance

31 August 2024 (15:40 - 15:50)

Organised by:

About the speaker

Professor Azfar Zaman

Freeman Hospital, Newcastle-Upon-Tyne (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail

Introduction; a clinical case of a patient with ASCVD and high triglyceride levels

Professor P. Steg (Paris, FR)

Presentation thumbnail

Understanding the role of triglycerides in the assessment of residual risk

Professor A. Zambon (Padua, IT)

Presentation thumbnail

Managing a patient with residual risk: applying recent evidence with EPA to practice

Professor K. Ray (London, GB)

Presentation thumbnail

Discussion: 5 burning questions from the audience

Presentation thumbnail

The 5 key take home messages

Access the full session

Session thumbnail

Clinical scenarios addressing residual risk in atherosclerotic cardiovascular disease (ASCVD): understanding the role of triglycerides and eicosapentaenoic acid (EPA)

The Event

Event poster

ESC Congress 2024

31 August 2024 15:40 CET

You may be interested in

Congress Presentation

Integrating icosapent ethyl in cardiovascular risk reduction strategies: practical guidance

Congress Session

Clinical scenarios addressing residual risk in atherosclerotic cardiovascular disease (ASCVD): understanding the role of triglycerides and eicosapentaenoic acid (EPA)

Congress Presentation

State-of-the-art lecture beyond antithrombotic therapies in PCI: role of lipids, inflammation, and therapies on the horizon

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources